Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adaptive Osimertinib Treatment in EGFRm NSCLC
NCT07058519Phase 2Recruiting
- Sponsor
- Shanghai Chest Hospital
- Start
- Sep 2025
- Primary completion
- Jan 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of osimertinib in non-small cell lung cancer (NSCLC), sponsored by Shanghai Chest Hospital. Started Sep 2025; status: recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07058519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07058519.